Global Neuroprosthetics Market Size, Share, Opportunities, And Trends By Type (Output Neural Prosthetics, Input Neural Prosthetics), By Technique (Deep Brain Stimulation, Spinal Cord Stimulation, Sacral Nerve Stimulation, Transcranial Magnetic Stimulation, Vague Nerve Stimulation), By Application (Auditory Processing Disorders, Parkison’s Disease, Epilepsy, Ophthalmic Disease, Cardiovascular Disease, Paralysis, Alzheimer's Disease, Others), And By Geography - Forecasts From 2025 To 2030

The global neuroprosthetics market is expected to grow at a CAGR of 12.91%, reaching a market size of US$14.927 billion in 2030 from US$8.645 billion in 2025.

Neuroprosthetics are devices implanted in patients with neural damage to compensate for and restore the normal functioning of the nerves, which consequently help in partially restoring normal bodily functions. The rising incidences of neurological disorders worldwide are one of the major factors anticipated to boost the global neuroprosthetics market growth during the forecast period. The market includes various types of devices, such as brain-machine interfaces, spinal cord stimulators, cochlear implants, deep brain stimulators, and retinal implants. Key players include established medical device companies and emerging startups.

Regulatory approvals from health authorities like the FDA and EMA ensure safety and efficacy. Technological challenges include developing devices for complex neural networks, ethical considerations, privacy issues, and societal acceptance. Furthermore, the growing number of diabetes patients, leading to nerve damage in many people, is also expected to lead to a surge in demand for neuroprosthetics in the coming years. Moreover, the number of people with disabling hearing loss has been increasing substantially over the years, and its projected rapid rise in the coming years is further anticipated to augment the global neuroprosthetics market growth during the assessment period.

Market Drivers:

• Rising cases of neurological disorders are expected to increase the global neuroprosthetics market.

The number of people suffering from neurological disorders is on the rise worldwide and is one of the prominent reasons anticipated to drive the demand for neuroprosthetics during the forecast period. According to the World Health Organization, the number of deaths caused by neurological disorders has increased by nearly 39% in the last 30 years. It has also been stated that an increase in the number of patients with neurological disorders has been seen over the years, while the number of cases is further projected to grow in the coming years owing to a growing elderly population, a decrease in child mortality, and rise in the survival rate and life expectancy.

As per data from the Pan America Health Organization (PAHO), the years lived with disability (YLDs) per 100,000 population in Brazil increased from 784.06 years in 2010 to 813.74 years in 2019. In Mexico, it increased from 721.78 years in 2010 to 737.02 years in 2019. In the United States, the deaths from neurological disorders increased from 39.29 deaths per 100,000 population in 2010 to 47.39 deaths in 2019, witnessing an increase of more than 20%.

Furthermore, diseases such as Alzheimer's, dementia, and Parkinson’s disease are some of the neurological disorders spreading fast. For instance, according to PAHO, Canada has witnessed a surge in disability-adjusted life years (DALYs) per 100,000 population from 351.30 in 2010 to 415.70 in 2019, growing by more than 18%.

• The growing prevalence of hearing loss would lead to a surge in neuroprosthetics demand.

As neuroprosthetics are used in severe hearing loss, the increasing prevalence of hearing loss worldwide is a significant factor expected to augment the global neuroprosthetics market growth in the coming years. According to data from the WHO, the absolute number of people with hearing loss in Brazil has increased from 10 million in 2008 to 13 million in 2018.

In China, the number of people with hearing loss increased from 74 million in 2008 to 96 million in 2018, while in India, this number increased from 76.5 million in 2008 to 100 million in 2018. WHO has projected that people with disabling hearing loss will increase from 430 million in 2020 to more than 700 million by 2050. This is expected to surge the demand for neuroprosthetics significantly.

Asia Pacific region is projected to have a major market share.

Geographically, the Asia Pacific region is anticipated to hold a significant market share owing to the rising cases of neurological disorders in the region. Furthermore, the presence of a quality healthcare system and its accessibility to patients make diagnosis and treatment stronger, which is another prominent reason for the large market size of neuroprosthetics in the region. The Asia Pacific region is anticipated to witness substantial growth due to the rising prevalence of hearing loss in the region.

Additionally, according to data from the WHO, the absolute number of people with disabling hearing loss in South Asia is projected to increase from 131 million in 2018 to 176 million in 2030 and further to 267 million in 2050. Furthermore, the rapidly growing cases of diabetes in the region are leading to damage to the nerves and blood vessels of a large number of patients, which is further projected to surge the demand for neuroprosthetics in the Asia Pacific region during the assessment period.

Key Developments:

• January 2024- Rice University and Houston Methodist established the Center for Neural Systems Restoration (CNSR), a joint interdisciplinary center for neuroscience research and treatment innovation. The center aims to improve neurological care by bringing together scientists, clinicians, engineers, and surgeons to tackle medical challenges like stroke recovery and spinal cord injury. Key focus areas include brain function restoration, mild traumatic brain injury detection, mobility restoration, balance, and biofeedback training. The Houston Methodist facility included operating rooms, a laboratory for diagnosis and assessment, device fabrication and testing, and education and training opportunities.
• March 2023- Cochlear, a global leader in implantable hearing solutions, become the first hearing implant manufacturer to receive ISO/IEC 27001 certification for information security management. This certification assesses data protection and demonstrates Cochlear's commitment to global best practices. The certification also signifies Cochlear's commitment to high standards in digital products, such as its Connected Care, which offers convenient care options through Smart Apps and software solutions, enhancing surgeons' confidence in device placement and optimizing postoperative clinical performance.
• December 2022- The Saskatchewan Government, the Ministry of Health, and the Saskatchewan Health Authority (SHA) launched an expanded Cochlear Implant Program to assist individuals with severe hearing loss who need their external sound processor replaced. The program allows individuals to co-pay $840 per processor, with the Ministry of Health covering the remaining cost, typically $8,000 to $12,000. The program covers approximately 70 sound processors in the next few months and 50 devices per year thereafter. The program is expected to cost $446,000 in 2022-23, with an annual cost of $300,000.

Neuroprosthetics Market Scope:

Report Metric	Details
Market Size Value in 2025	US$8.645 billion
Market Size Value in 2030	US$14.927 billion
Growth Rate	CAGR of 12.91%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segments Covered	Type Technique Application Geography
Companies Covered	SenArs LivaNova PLC Medtronic PLC Sonova Holding AG Boston Scientific Corporation
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Customization Scope	Free report customization with purchase

Market Segmentation:

• By Type
  • Output Neural Prosthetics
  • Input Neural Prosthetics
• By Technique
  • Deep Brain Stimulation
  • Spinal Cord Stimulation
  • Sacral Nerve Stimulation
  • Transcranial Magnetic Stimulation
  • Vague Nerve Stimulation
• By Application
  • Auditory Processing Disorders
  • Parkison’s Disease
  • Epilepsy
  • Ophthalmic Disease
  • Cardiovascular Disease
  • Paralysis
  • Alzheimer's Disease
  • Others
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. GLOBAL NEUROPROSTHETICS MARKET BY TYPE

5.1. Introduction

5.2. Output Neural Prosthetics

5.2.1. Market Opportunities and Trends

5.2.2. Growth Prospects

5.2.3. Geographic Lucrativeness

5.3. Input Neural Prosthetics

5.3.1. Market Opportunities and Trends

5.3.2. Growth Prospects

5.3.3. Geographic Lucrativeness

6. GLOBAL NEUROPROSTHETICS MARKET BY TECHNIQUE

6.1. Introduction

6.2. Deep Brain Stimulation

6.2.1. Market Opportunities and Trends

6.2.2. Growth Prospects

6.2.3. Geographic Lucrativeness

6.3. Spinal Cord Stimulation

6.3.1. Market Opportunities and Trends

6.3.2. Growth Prospects

6.3.3. Geographic Lucrativeness

6.4. Sacral Nerve Stimulation

6.4.1. Market Opportunities and Trends

6.4.2. Growth Prospects

6.4.3. Geographic Lucrativeness

6.5. Transcranial Magnetic Stimulation

6.5.1. Market Opportunities and Trends

6.5.2. Growth Prospects

6.5.3. Geographic Lucrativeness

6.6. Vague Nerve Stimulation

6.6.1. Market Opportunities and Trends

6.6.2. Growth Prospects

6.6.3. Geographic Lucrativeness

7. GLOBAL NEUROPROSTHETICS MARKET BY APPLICATION

7.1. Introduction

7.2. Auditory Processing Disorders

7.2.1. Market Opportunities and Trends

7.2.2. Growth Prospects

7.2.3. Geographic Lucrativeness

7.3. Parkison’s Disease

7.3.1. Market Opportunities and Trends

7.3.2. Growth Prospects

7.3.3. Geographic Lucrativeness

7.4. Epilepsy

7.4.1. Market Opportunities and Trends

7.4.2. Growth Prospects

7.4.3. Geographic Lucrativeness

7.5. Ophthalmic Disease

7.5.1. Market Opportunities and Trends

7.5.2. Growth Prospects

7.5.3. Geographic Lucrativeness

7.6. Cardiovascular Disease

7.6.1. Market Opportunities and Trends

7.6.2. Growth Prospects

7.6.3. Geographic Lucrativeness

7.7. Paralysis

7.7.1. Market Opportunities and Trends

7.7.2. Growth Prospects

7.7.3. Geographic Lucrativeness

7.8. Alzheimer's Disease

7.8.1. Market Opportunities and Trends

7.8.2. Growth Prospects

7.8.3. Geographic Lucrativeness

7.9. Others

7.9.1. Market Opportunities and Trends

7.9.2. Growth Prospects

7.9.3. Geographic Lucrativeness

8. GLOBAL NEUROPROSTHETICS MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Type

8.2.2. By Technique

8.2.3. By Application

8.2.4. By Country

8.2.4.1. USA

8.2.4.1.1. Market Opportunities and Trends

8.2.4.1.2. Growth Prospects

8.2.4.2. Canada

8.2.4.2.1. Market Opportunities and Trends

8.2.4.2.2. Growth Prospects

8.2.4.3. Mexico

8.2.4.3.1. Market Opportunities and Trends

8.2.4.3.2. Growth Prospects

8.3. South America

8.3.1. By Type

8.3.2. By Technique

8.3.3. By Application

8.3.4. By Country 

8.3.4.1. Brazil

8.3.4.1.1. Market Opportunities and Trends

8.3.4.1.2. Growth Prospects

8.3.4.2. Argentina

8.3.4.2.1. Market Opportunities and Trends

8.3.4.2.2. Growth Prospects

8.3.4.3. Others

8.3.4.3.1. Market Opportunities and Trends

8.3.4.3.2. Growth Prospects

8.4. Europe

8.4.1. By Type

8.4.2. By Technique

8.4.3. By Application

8.4.4. By Country

8.4.4.1. Germany

8.4.4.1.1. Market Opportunities and Trends

8.4.4.1.2. Growth Prospects

8.4.4.2. France

8.4.4.2.1. Market Opportunities and Trends

8.4.4.2.2. Growth Prospects

8.4.4.3. United Kingdom

8.4.4.3.1. Market Opportunities and Trends

8.4.4.3.2. Growth Prospects

8.4.4.4. Others

8.4.4.4.1. Market Opportunities and Trends

8.4.4.4.2. Growth Prospects

8.5. Middle East and Africa

8.5.1. By Type

8.5.2. By Technique

8.5.3. By Application

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.1.1. Market Opportunities and Trends

8.5.4.1.2. Growth Prospects

8.5.4.2. UAE

8.5.4.2.1. Market Opportunities and Trends

8.5.4.2.2. Growth Prospects

8.5.4.3. Others

8.5.4.3.1. Market Opportunities and Trends

8.5.4.3.2. Growth Prospects

8.6. Asia Pacific

8.6.1. By Type

8.6.2. By Technique

8.6.3. By Application

8.6.4. By Country

8.6.4.1. China

8.6.4.1.1. Market Opportunities and Trends

8.6.4.1.2. Growth Prospects

8.6.4.2. India

8.6.4.2.1. Market Opportunities and Trends

8.6.4.2.2. Growth Prospects

8.6.4.3. Japan

8.6.4.3.1. Market Opportunities and Trends

8.6.4.3.2. Growth Prospects

8.6.4.4. South Korea

8.6.4.4.1. Market Opportunities and Trends

8.6.4.4.2. Growth Prospects

8.6.4.5. Taiwan

8.6.4.5.1. Market Opportunities and Trends

8.6.4.5.2. Growth Prospects

8.6.4.6. Thailand

8.6.4.6.1. Market Opportunities and Trends

8.6.4.6.2. Growth Prospects

8.6.4.7. Indonesia

8.6.4.7.1. Market Opportunities and Trends

8.6.4.7.2. Growth Prospects

8.6.4.8. Others

8.6.4.8.1. Market Opportunities and Trends

8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. SenArs

10.2. LivaNova PLC

10.3. Medtronic PLC

10.4. Sonova Holding AG

10.5. Boston Scientific Corporation

10.6. Cochlear Ltd

10.7. Demant AS

10.8. Abbott Laboratories

10.9. NeuroPace, Inc.

10.10. BrainGate

10.11. NDI Medical

SenArs

LivaNova PLC

Medtronic PLC

Sonova Holding AG

Boston Scientific Corporation

Cochlear Ltd

Demant AS

Abbott Laboratories

NeuroPace, Inc.

BrainGate

NDI Medical